E. V. Glazkova
Research Subjects
E. V. Glazkova has a total of 52 co-authors. Here are the top co-authors by number of shared publications:
- Mona A. Frolova
N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
3 shared publications - Alexey A. Rumyantsev
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - E. R. Israyelyan
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Ilya A. Pokataev
Oncology Center No. 1 of the City Clinical Hospital named after S. S. Yudin of the Moscow Department of Health
2 shared publications - Sergei A. Tjulandin
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications - Tatiana E. Tikhomirova
N.N. Blokhin National Medical Research Center of Oncology, Ministry of Health of Russia
2 shared publications
Latest Publications
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 53-61
Maintenance therapy with avelumab for metastatic urothelial cancer: data from real clinical practice
Introduction . Platinum-based chemotherapy (CT) remains the first-line standard of care for metastatic urothelial cancer (mUC). Maintenance therapy with avelumab, based on the JAVELIN Bladder 100 trial, has demonstrated an overall survival (OS) benefit. However, patients in real-world clinical practice often differ from those enrolled in registration trials, which limits the extrapolation of these data. Objective . To demonstrate the long-term outcomes of patients with mUC in real-world clinical practice who are candidates for avelumab maintenance therapy, depending on the management strategy (immunotherapy versus active surveillance), and to evaluate second-line therapy administered upon disease progression in both groups. Materials and Methods . This retrospective multicenter study included platinum-eligible patients aged > 18 years with confirmed mUC who had no disease progression after completing 4–6 cycles of first-line chemotherapy with gemcitabine / cisplatin (GemCis) or gemcitabine / carboplatin (GemCarb). Patients were divided into two groups according to subsequent management: those who received avelumab maintenance therapy and those who were placed under active surveillance. Treatment continued until disease progression or unacceptable toxicity. Upon progression, the choice of subsequent therapy was at the treating physician's discretion. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoint was OS. Results . A total of 115 patients were included in the study. Of these, 70 patients (61 %) received avelumab maintenance therapy, while 45 patients (39 %) were placed under active surveillance. At a median follow-up of 26 months, the 1-year PFS rates were 37.5 % and 16.7 % in the avelumab and surveillance groups, respectively. Median PFS was 6.4 months in the maintenance therapy group and 3.8 months in the surveillance group (HR 0.45, 95 % CI 0.28–0.73; p = 0.0012). The 1-year OS rates were 60.4 % and 53.1 % for patients receiving avelumab and those under surveillance, respectively. Median OS in the above groups was 16.1 months and 12.7 months (HR 0.88, 95 % CI 0.53–1.47; p = 0.65). Disease progression occurred less frequently in the avelumab group (63 % vs. 87 %, p = 0.01), while the proportion of patients who received second-line therapy was higher in this group (68 % vs. 44 %, p = 0.042). In the avelumab group, taxanes (56 %) and platinum-based CT (30 %) were the most common second-line regimens, whereas immunotherapy (76 %) predominated in the surveillance group. Conclusion . Our findings confirm that the strategy of avelumab maintenance immunotherapy after first-line platinum-based chemotherapy for metastatic UC is an effective approach in real-world clinical practice.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 53-61
Open AccessMaintenance therapy with avelumab for metastatic urothelial cancer: data from real clinical practice
Introduction . Platinum-based chemotherapy (CT) remains the first-line standard of care for metastatic urothelial cancer (mUC). Maintenance therapy with avelumab, based on the JAVELIN Bladder 100 trial, has demonstrated an overall survival (OS) benefit. However, patients in real-world clinical practice often differ from those enrolled in registration trials, which limits the extrapolation of these data. Objective . To demonstrate the long-term outcomes of patients with mUC in real-world clinical practice who are candidates for avelumab maintenance therapy, depending on the management strategy (immunotherapy versus active surveillance), and to evaluate second-line therapy administered upon disease progression in both groups. Materials and Methods . This retrospective multicenter study included platinum-eligible patients aged > 18 years with confirmed mUC who had no disease progression after completing 4–6 cycles of first-line chemotherapy with gemcitabine / cisplatin (GemCis) or gemcitabine / carboplatin (GemCarb). Patients were divided into two groups according to subsequent management: those who received avelumab maintenance therapy and those who were placed under active surveillance. Treatment continued until disease progression or unacceptable toxicity. Upon progression, the choice of subsequent therapy was at the treating physician's discretion. The primary endpoint was 1-year progression-free survival (PFS). The secondary endpoint was OS. Results . A total of 115 patients were included in the study. Of these, 70 patients (61 %) received avelumab maintenance therapy, while 45 patients (39 %) were placed under active surveillance. At a median follow-up of 26 months, the 1-year PFS rates were 37.5 % and 16.7 % in the avelumab and surveillance groups, respectively. Median PFS was 6.4 months in the maintenance therapy group and 3.8 months in the surveillance group (HR 0.45, 95 % CI 0.28–0.73; p = 0.0012). The 1-year OS rates were 60.4 % and 53.1 % for patients receiving avelumab and those under surveillance, respectively. Median OS in the above groups was 16.1 months and 12.7 months (HR 0.88, 95 % CI 0.53–1.47; p = 0.65). Disease progression occurred less frequently in the avelumab group (63 % vs. 87 %, p = 0.01), while the proportion of patients who received second-line therapy was higher in this group (68 % vs. 44 %, p = 0.042). In the avelumab group, taxanes (56 %) and platinum-based CT (30 %) were the most common second-line regimens, whereas immunotherapy (76 %) predominated in the surveillance group. Conclusion . Our findings confirm that the strategy of avelumab maintenance immunotherapy after first-line platinum-based chemotherapy for metastatic UC is an effective approach in real-world clinical practice.
- Open Access
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Frontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- 25 October 2026
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 16 (3) , 35-43
Open AccessFrontline maintenance olaparib therapy for BRCA/HRD-positive advanced epithelial ovarian cancer: real-world data analysis in matched population
Background . Introduction of the poly(ADP-ribose) polymerase (PARP) inhibitors to clinical practice remarkably improved outcomes for advanced epithelial ovarian cancer (EOC) patients. We conducted this study to evaluate efficacy of frontline maintenance olaparib therapy in BRCA-mutated and / or HRD-positive EOC patients in real-world practice setting. Patients and methods. We enrolled patients with FIGO stage III–IV high-grade serous or endometrioid EOC with BRCA1 / 2 mutations and / or HRD-positive status with complete or partial response to frontline therapy, who were treated in 2014–2024. Main objective of this trial was to compare progression-free survival (PFS) of HRD+ / BRCA-mutant advanced EOC patients treated with or without maintenance olaparib in well-balanced treatment arms. Cardinality matching was considered to ensure balancing of the study arms with 1:1 ratio of patients in trial arms. The groups were balanced according to the presence of residual tumor after initial treatment, platinum-free interval duration after frontline therapy, secondary local therapy for recurrent disease, treatment with platinum drugs for relapse and subsequent bevacizumab. The primary endpoint of the study was PFS. Results. Cardinality matching with 1:1 ratio resulted in 282 matched patients for the analysis. Groups were well balanced in all baseline characteristics. Median age in both treatment arms was 50 years with no differences in patients' age, surgical outcomes, prevalence of BRCA-mutated or HRD-positive disease and response to initial platinum-based therapy. With a median follow up of 37.2 mo. median PFS was 38.0 in the olaparib arm and 13.7 mo. in the control arm, respectively (HR 0.32; 95 % CI 0.23–0.43; p < 0.001). Estimated 3-year PFS was 50.9 % and 11.5 %, respectively. Median PFS2 was 49.5 mo. in the olaparib arm compared to 34.3 mo. in the control arm (HR 0.58; 95 % CI 0.39–0.85; p = 0.005). Conclusion. This study confirms the benefits of olaparib maintenance therapy in patients with HRD-positive and / or BRCA-mutated advanced EOC in real-world setting.
- Open Access
- 30 November 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3s1) , 31-37
Предварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом
Цель исследования: Изучить эффективность и переносимость терапии по схеме FOLFOX с дабрафенибом и цетуксимабом/панитумумабом в 1 линии терапии метастатического колоректального рака (мКРР) с мутацией в гене BRAF и MSS фенотипом. Методы: Нерандомизрованное многоцентровое несравнительное исследование II фазы по изучению эффективности и безопасности терапии комбинацией режима FOLFOX с дабрафенибом и анти-EGFR в первой линии лечения мКРР с мутацией в гене BRAF и MSS фенотипом. Основные критерии включения: пациенты с гистологически подтвержденным мКРР с мутацией в гене BRAF и MSS фенотипом, удовлетворительной функцией кроветворения и основных показателей внутренних органов, наличием измеряемых проявлений болезни в соответствии с критериями RECIST 1.1. Статистическая гипотеза: нулевая гипотеза — частота объективных ответов 40 %, альтернативная гипотеза — частота объективных ответов 60 %. Для принятия альтернативной гипотезы, при ошибке первого рода 0,05, мощности исследования 90 необходимо включить в исследование 64 пациента. В настоящей статье мы представляем предварительные результаты исследования (NCT06978400). Результаты: На момент сообщения в исследование включено 13 пациентов с мКРР, имеющих мутацию в гене BRAF, ранее не получавших противоопухолевое лечение. Медиана времени наблюдения составила 4,0 месяца (мин. 2 мес. — макс. 19 мес.; 1,4). Соматический статус по шкале ECOG 0 баллов на момент включения в исследование имели 3 пациента (23,1 %), ECOG 1 балл — 9 (69,2 %), ECOG 2 балла 1 пациент (7,7 %). Частичный опухолевый ответ (ЧОО) достигнут у 6 пациентов. Частота объективных ответов в ITT популяции (n = 13) составила 46,1 %. Эффект лечения оценен у 10 (76,9 %). Один пациент умер после 2 курсов лечения от перфорации опухоли, 1 пациент прекратил лечение из‑за токсичности после 1‑ого курса. У 4 пациентов зарегистрирована стабилизация опухолевого процесса (40 %), частичный опухолевый ответ (ЧОО) описан у 6 (60 %) пациентов. Медиана времени до наступления ЧОО с момента начала лечения составила 2 месяца (2,0–4,0).Токсичность описана у 13 (100 %) пациентов в нашем исследовании. Всего на момент анализа данных зарегистрировано 39 нежелательных явлений (НЯ) всех степеней, из них случаев НЯ I–II степени 32 (82 %), III–IV степени — 7 (18,0 %). Отмена лечения потребовалась 1 пациенту в связи с пирексией IV степени. Выводы: Комбинация режима FOLFOX с дабрафенибом и анти-EGFR при первичном анализе демонстрирует управляемый профиль токсичности, высокую частоту контроля над заболеванием.
- 30 November 2025
- Published by Russian Society of Clinical Oncology in Malignant tumours
- Vol. 15 (3s1) , 31-37
Open AccessПредварительные результаты нерандомизированного многоцентрового исследования II фазы комбинации FOLFOX с панитумумабом/цетуксимабом и дабрафенибом в первой линии лечения метастатического колоректального рака с мутацией в гене BRAF и MSS фенотипом
Цель исследования: Изучить эффективность и переносимость терапии по схеме FOLFOX с дабрафенибом и цетуксимабом/панитумумабом в 1 линии терапии метастатического колоректального рака (мКРР) с мутацией в гене BRAF и MSS фенотипом. Методы: Нерандомизрованное многоцентровое несравнительное исследование II фазы по изучению эффективности и безопасности терапии комбинацией режима FOLFOX с дабрафенибом и анти-EGFR в первой линии лечения мКРР с мутацией в гене BRAF и MSS фенотипом. Основные критерии включения: пациенты с гистологически подтвержденным мКРР с мутацией в гене BRAF и MSS фенотипом, удовлетворительной функцией кроветворения и основных показателей внутренних органов, наличием измеряемых проявлений болезни в соответствии с критериями RECIST 1.1. Статистическая гипотеза: нулевая гипотеза — частота объективных ответов 40 %, альтернативная гипотеза — частота объективных ответов 60 %. Для принятия альтернативной гипотезы, при ошибке первого рода 0,05, мощности исследования 90 необходимо включить в исследование 64 пациента. В настоящей статье мы представляем предварительные результаты исследования (NCT06978400). Результаты: На момент сообщения в исследование включено 13 пациентов с мКРР, имеющих мутацию в гене BRAF, ранее не получавших противоопухолевое лечение. Медиана времени наблюдения составила 4,0 месяца (мин. 2 мес. — макс. 19 мес.; 1,4). Соматический статус по шкале ECOG 0 баллов на момент включения в исследование имели 3 пациента (23,1 %), ECOG 1 балл — 9 (69,2 %), ECOG 2 балла 1 пациент (7,7 %). Частичный опухолевый ответ (ЧОО) достигнут у 6 пациентов. Частота объективных ответов в ITT популяции (n = 13) составила 46,1 %. Эффект лечения оценен у 10 (76,9 %). Один пациент умер после 2 курсов лечения от перфорации опухоли, 1 пациент прекратил лечение из‑за токсичности после 1‑ого курса. У 4 пациентов зарегистрирована стабилизация опухолевого процесса (40 %), частичный опухолевый ответ (ЧОО) описан у 6 (60 %) пациентов. Медиана времени до наступления ЧОО с момента начала лечения составила 2 месяца (2,0–4,0).Токсичность описана у 13 (100 %) пациентов в нашем исследовании. Всего на момент анализа данных зарегистрировано 39 нежелательных явлений (НЯ) всех степеней, из них случаев НЯ I–II степени 32 (82 %), III–IV степени — 7 (18,0 %). Отмена лечения потребовалась 1 пациенту в связи с пирексией IV степени. Выводы: Комбинация режима FOLFOX с дабрафенибом и анти-EGFR при первичном анализе демонстрирует управляемый профиль токсичности, высокую частоту контроля над заболеванием.
- Open Access
- 31 July 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 158-165
Experience of using talazoparib in the aggressive course of BRCA2-associated triple-negative breast cancer: a clinical observation
The median overall survival for patients with metastatic triple-negative breast cancer is about 12-14 months. Chemotherapy has been the only treatment option for this tumour subtype for a long time, irrespective of immunological and genetic characteristics. Straightforward therapy algorithms have not been defined, and the optimum sequencing of chemotherapy regimens is left to the discretion of the attending physician. Today, impressive findings from clinical studies on the use of immunotherapy and targeted therapy for cancer using PARP inhibitors reflect in current guidelines, raising the chances of patients to prolong life and maintain its high quality. Thus, the use of immunotherapy as first-line treatment of PD-L1-positive tumours allowed to significantly increase the overall survival of patients for the first time in many years. And the use of PARP inhibitors in carriers of BRCA1/2 germline mutations not only significantly prolongs progression-free survival, but also improves quality of life versus standard chemotherapy regimens. The benefit is also observed in patients with an aggressive course of the disease such as damage to the visceral organs and the central nervous system. The presence of BRCA1/2 germline mutations in the genes, damage to the CNS and visceral organs is associated with an extremely unfavourable prognosis and a significant decline in life expectancy. However, a high-quality diagnosis before initiation of treatment, creating proper treatment plans and the use of modern opportunities can improve the outcomes of treatment. The article discusses possible treatment options for metastatic TNBC, reflects current guidelines on the use of immuno- and targeted therapy. A clinical case report of the treatment of a patient with a significantly aggravated history and an aggressive course of TNBC is presented. The patient with visceral metastases, brain damage and early progression after primary treatment has been receiving therapy for two years, while maintaining a satisfactory quality of life.
- 31 July 2023
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 11,p. 158-165
Open AccessExperience of using talazoparib in the aggressive course of BRCA2-associated triple-negative breast cancer: a clinical observation
The median overall survival for patients with metastatic triple-negative breast cancer is about 12-14 months. Chemotherapy has been the only treatment option for this tumour subtype for a long time, irrespective of immunological and genetic characteristics. Straightforward therapy algorithms have not been defined, and the optimum sequencing of chemotherapy regimens is left to the discretion of the attending physician. Today, impressive findings from clinical studies on the use of immunotherapy and targeted therapy for cancer using PARP inhibitors reflect in current guidelines, raising the chances of patients to prolong life and maintain its high quality. Thus, the use of immunotherapy as first-line treatment of PD-L1-positive tumours allowed to significantly increase the overall survival of patients for the first time in many years. And the use of PARP inhibitors in carriers of BRCA1/2 germline mutations not only significantly prolongs progression-free survival, but also improves quality of life versus standard chemotherapy regimens. The benefit is also observed in patients with an aggressive course of the disease such as damage to the visceral organs and the central nervous system. The presence of BRCA1/2 germline mutations in the genes, damage to the CNS and visceral organs is associated with an extremely unfavourable prognosis and a significant decline in life expectancy. However, a high-quality diagnosis before initiation of treatment, creating proper treatment plans and the use of modern opportunities can improve the outcomes of treatment. The article discusses possible treatment options for metastatic TNBC, reflects current guidelines on the use of immuno- and targeted therapy. A clinical case report of the treatment of a patient with a significantly aggravated history and an aggressive course of TNBC is presented. The patient with visceral metastases, brain damage and early progression after primary treatment has been receiving therapy for two years, while maintaining a satisfactory quality of life.
- Open Access
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 201-206
Therapy options for metastatic triple negative breast cancer
Metastatic triple-negative breast cancer remains the most unfavourable among all breast cancer subtypes from the prognostic point of view. Despite the active introduction into practice of combinations of cytostatics with immunotherapeutic agents, as well as PARP inhibitors, sequential lines of chemotherapy with the median overall survival which does not exceed 15 months remains the main method of treating patients in this group. This breast cancer subtype is characterized by a rapid development of drug resistance at the early stages of systemic treatment and a predominantly visceral progression, which determines a low life expectancy in patients. The combination of capecitabine and ixabepilone has proved to be effective in the treatment of tumours that are resistant to taxanes and anthracyclines. The use of this combination is characterized by an acceptable and controlled toxicity profile. This article presents a clinical case of therapy with a combination of ixabepilone and capecitabine of a patient with breast cancer progression during the previous therapy of taxanes, a platinum-based doublet chemotherapy and eribulin. This approach, together with symptomatic laparocentesis and pleurodesis, allowed for overall survival exceeding 45 months with the preservation of a satisfactory functional status of the patient.
- 19 June 2022
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 201-206
Open AccessTherapy options for metastatic triple negative breast cancer
Metastatic triple-negative breast cancer remains the most unfavourable among all breast cancer subtypes from the prognostic point of view. Despite the active introduction into practice of combinations of cytostatics with immunotherapeutic agents, as well as PARP inhibitors, sequential lines of chemotherapy with the median overall survival which does not exceed 15 months remains the main method of treating patients in this group. This breast cancer subtype is characterized by a rapid development of drug resistance at the early stages of systemic treatment and a predominantly visceral progression, which determines a low life expectancy in patients. The combination of capecitabine and ixabepilone has proved to be effective in the treatment of tumours that are resistant to taxanes and anthracyclines. The use of this combination is characterized by an acceptable and controlled toxicity profile. This article presents a clinical case of therapy with a combination of ixabepilone and capecitabine of a patient with breast cancer progression during the previous therapy of taxanes, a platinum-based doublet chemotherapy and eribulin. This approach, together with symptomatic laparocentesis and pleurodesis, allowed for overall survival exceeding 45 months with the preservation of a satisfactory functional status of the patient.
- Open Access
- 30 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 57-61-61
PARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
Около 10% всех случаев рака молочной железы (РМЖ) возникает у носителей мутаций в генах BRCA1/2. Ведущей функцией белковых продуктов генов BRCA1/2 является восстановление двунитевых разрывов ДНК посредством процесса гомологичной репарации. Поли-(АДФ рибоза)-полимеразы (PARP) также вовлечены в процесс репарации ДНК. Их функцией является восстановление однонитевых разрывов ДНК путем эксцизионной репарации оснований. PARPингибиторы представляют собой современную опцию лечения метастатического BRCA-ассоциированного HER2- негативного РМЖ. Их действие основано на принципе «синтетической летальности» в условиях дисфункции BRCA, когда нарушаются оба процесса репарации ДНК, – гомологичная рекомбинация и эксцизионная репарация оснований. Это приводит к апоптозу опухолевых клеток. В настоящее время в России для лечения метастатического BRCAассоциированного HER2-негативного РМЖ зарегистрированы 2 PARP-ингибитора – олапариб и талазопариб. Эффективность олапариба и талазопариба, по сравнению со стандартной химиотерапией, изучалась в схожих по дизайну исследованиях III фазы OlympiAD и EMBRACA. Выигрыш в выживаемости, приемлемый профиль токсичности, а также положительное влияние на качество жизни позволяют рекомендовать использование PARP-ингибиторов в схемах лечения метастатического BRCAассоциированного РМЖ. Очень важна роль PARP-ингибиторов в лечении метастатического тройного негативного РМЖ, учитывая агрессивное течение данного подтипа и ограниченное количество эффективных опций терапии. Мы представляем клинический случай применения талазопариба в качестве 4-й линии терапии у больной метастатическим тройным негативным РМЖ.
- 30 July 2020
- Published by Remedium, Ltd. in Meditsinskiy sovet = Medical Council
- No. 9,p. 57-61-61
Open AccessPARP inhibitors in the treatment of metastatic breast cancer patients with germline BRCA1/2 mutations. Experience of treatment with talazoparib in clinical practice
Около 10% всех случаев рака молочной железы (РМЖ) возникает у носителей мутаций в генах BRCA1/2. Ведущей функцией белковых продуктов генов BRCA1/2 является восстановление двунитевых разрывов ДНК посредством процесса гомологичной репарации. Поли-(АДФ рибоза)-полимеразы (PARP) также вовлечены в процесс репарации ДНК. Их функцией является восстановление однонитевых разрывов ДНК путем эксцизионной репарации оснований. PARPингибиторы представляют собой современную опцию лечения метастатического BRCA-ассоциированного HER2- негативного РМЖ. Их действие основано на принципе «синтетической летальности» в условиях дисфункции BRCA, когда нарушаются оба процесса репарации ДНК, – гомологичная рекомбинация и эксцизионная репарация оснований. Это приводит к апоптозу опухолевых клеток. В настоящее время в России для лечения метастатического BRCAассоциированного HER2-негативного РМЖ зарегистрированы 2 PARP-ингибитора – олапариб и талазопариб. Эффективность олапариба и талазопариба, по сравнению со стандартной химиотерапией, изучалась в схожих по дизайну исследованиях III фазы OlympiAD и EMBRACA. Выигрыш в выживаемости, приемлемый профиль токсичности, а также положительное влияние на качество жизни позволяют рекомендовать использование PARP-ингибиторов в схемах лечения метастатического BRCAассоциированного РМЖ. Очень важна роль PARP-ингибиторов в лечении метастатического тройного негативного РМЖ, учитывая агрессивное течение данного подтипа и ограниченное количество эффективных опций терапии. Мы представляем клинический случай применения талазопариба в качестве 4-й линии терапии у больной метастатическим тройным негативным РМЖ.
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 1074
Neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and paclitaxel in patients with early triple-negative breast cancer (TNBC).
1074 Background: TNBC is characterized by aggressive behavior and poor prognosis. It has been shown that achievement of pathological complete regression (pCR) after neoadjuvant chemotherapy improved survival of patients (pts) with TNBC. Rates of pCR with standard antracycline- and taxanebased chemotherapy regimens don’t exceed 20-27%. There are strong phenotypic and molecular similarities between BRCA1-related breast cancers and triple-negative sporadic tumors. Markers of BRCA1-dysfunction may predispose sensitivity to specific agents such as platinum salts. We performed a prospective trial to evaluate efficacy of dose-dense schedule of doxorubicin, cisplatin and paclitaxel in correlation with BRCA1-dysfunction in pts with early TNBC (NCT01672671). Methods: Pts with early TNBC (cT1-2N0-1M0) were treated with doxorubicin 25 mg/m2 iv weekly, cisplatin 30 mg/m2 iv weekly and paclitaxel 100 mg/m2 iv weekly for planned 8 weeks with G-CSF 300 mcg 2-4 days followed by surgery. Pathologic response was assessed in...
- 20 May 2015
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 33 (15_suppl) , 1074
Neoadjuvant chemotherapy with dose-dense doxorubicin, cisplatin, and paclitaxel in patients with early triple-negative breast cancer (TNBC).
1074 Background: TNBC is characterized by aggressive behavior and poor prognosis. It has been shown that achievement of pathological complete regression (pCR) after neoadjuvant chemotherapy improved survival of patients (pts) with TNBC. Rates of pCR with standard antracycline- and taxanebased chemotherapy regimens don’t exceed 20-27%. There are strong phenotypic and molecular similarities between BRCA1-related breast cancers and triple-negative sporadic tumors. Markers of BRCA1-dysfunction may predispose sensitivity to specific agents such as platinum salts. We performed a prospective trial to evaluate efficacy of dose-dense schedule of doxorubicin, cisplatin and paclitaxel in correlation with BRCA1-dysfunction in pts with early TNBC (NCT01672671). Methods: Pts with early TNBC (cT1-2N0-1M0) were treated with doxorubicin 25 mg/m2 iv weekly, cisplatin 30 mg/m2 iv weekly and paclitaxel 100 mg/m2 iv weekly for planned 8 weeks with G-CSF 300 mcg 2-4 days followed by surgery. Pathologic response was assessed in...